-+ 0.00%
-+ 0.00%
-+ 0.00%

Iovance: lifileucel combination therapy achieved an objective response rate of 62.5% in the phase 2 melanoma trial.

Zhitongcaijing·10/23/2026 14:25:05
Listen to the news
Iovance: lifileucel combination therapy achieved an objective response rate of 62.5% in the phase 2 melanoma trial.